RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -88.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -88.88% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -75.51% |
| SG&A Expenses | -7.51% | -7.51% | -- | -- | -69.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.52% | -5.52% | -- | -- | -66.62% |
| Operating Income | -2.45% | -2.45% | -- | -- | 59.84% |
| Income Before Tax | -94.92% | -94.92% | -- | -- | 4.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.92% | -94.92% | -- | -- | 4.95% |
| Earnings from Discontinued Operations | 68.20% | 68.20% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.64% | -47.64% | -- | -- | -33.84% |
| EBIT | -2.45% | -2.45% | -- | -- | 59.84% |
| EBITDA | -3.41% | -3.41% | -- | -- | 59.84% |
| EPS Basic | -- | 0.00% | 43.56% | 44.18% | 12.70% |
| Normalized Basic EPS | -- | -- | -- | -- | 38.00% |
| EPS Diluted | -- | 0.00% | 43.56% | 44.18% | 12.70% |
| Normalized Diluted EPS | -- | -- | -- | -- | 38.00% |
| Average Basic Shares Outstanding | -- | -- | 156.37% | -- | 53.32% |
| Average Diluted Shares Outstanding | 200.00% | 200.00% | 200.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |